Point72 Asset Management, L.P. 13D and 13G filings for Amylyx Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-06-25 5:24 pm Purchase | 2025-06-24 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Point72 Asset Management, L.P. | 4,717,709 5.300% | 3,669,366 (+350.02%) | Filing |
| 2025-05-15 3:52 pm Sale | 2025-03-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Point72 Asset Management, L.P. | 1,048,343 1.200% | -3,771,990 (-78.25%) | Filing |
| 2025-01-14 4:53 pm Purchase | 2025-01-13 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Point72 Asset Management, L.P. | 4,820,333 5.600% | 1,617,952 (+50.52%) | Filing |
| 2024-02-14 07:15 am Sale | 2023-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Point72 Asset Management, L.P. | 3,202,381 4.700% | -268,310 (-7.73%) | Filing |
| 2023-12-11 4:15 pm Purchase | 2023-11-29 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Point72 Asset Management, L.P. | 3,470,691 5.100% | 3,470,691 (New Position) | Filing |